###### Strengths and limitations of this study

-   This is the first study to summarise illness characteristics of a cohort of Polish chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) patients.

-   We used Fukuda criteria to indicate patients with CFS/ME.

-   Recruitment was based on self-identification in response to an advertisement in CFS/ME community support networks across Poland.

-   Methodologically, more robust epidemiological studies of fatigue and its consequences in the Polish population are now needed.

Introduction {#s1}
============

Diagnostics and treatment of the chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) present a challenge to specialists as this syndrome is not a clearly identified, uniform disease but a set of symptoms resembling those occurring in other diseases, in which a sense of chronic fatigue predominates. In some countries (eg, Poland), CFS/ME is diagnosed very rarely, which may be associated with the fact that the aetiology of the disease is still poorly known, and with diagnostic problems resulting from a lack of detailed and uniform guidelines allowing an unambiguous diagnosis and initiation of effective treatment in CFS/ME patients.

The available studies provide several diagnostic criteria based on a definition of the American Centers for Disease Control (CDC), the Oxford Criteria, or the Canadian Guidelines. Criteria proposed by CDC (Fukuda et al. 1994) are most commonly used as acceptable diagnostic criteria when recruiting CFS/ME patients for scientific studies. However, they are encumbered by several disadvantages (eg, fatigue experienced for at least 6 months), which---from the point of view of clinical practice---may delay a diagnosis in patients who do not meet this criterion precisely. The Oxford criteria propose a new diagnostic approach, focusing mainly on an aspect of mental rather than somatic fatigue. The Canadian criteria (CDC) expand the CFS/ME definition with additional diagnostic criteria, ie, postexertional malaise and presence of neurological, endocrine, cognitive and autonomic (orthostatic intolerance) disorders. The proposed CFS/ME definition, including malaise and symptoms exacerbation after exercise, allows differentiating CFS/ME patients from patients with depression or fibromyalgia. Alternative criteria, such as the International Consensus Criteria, disclose a further range of symptoms pertaining to the neurological, immunological, gastrointestinal and autonomic systems.

Its global prevalence, ranging between 0.4% and 2.5%, is growing; most commonly, it is observed in the group of 20--40 year olds, more frequently in professionally active women. CFS/ME is considered to be a common condition in countries such as the UK, Australia and the USA.[@R1] In the UK, it affects up to 250 000 individuals with frequencies reported of up to 0.2%.[@R3] In the UK, Fukuda-defined cases have a prevalence of 0.2%. In the USA, the prevalence of Fukuda-defined cases has been reported between 0.2%5% and 0.4%. Finding from the Australian cohort showed that from 535 patients diagnosed with CFS/ME by a primary care physician, 30.28% met Fukuda criteria. To date CFS/ME has neither been reported in Poland, nor its prevalence defined. There are currently no CFS/ME clinical services.

The aim of this study was to summarise sociodemographic and illness characteristics in those reporting CFS/ME symptoms in a Polish population. We set out to define the presence and characteristics of CFS/ME in Poland in order to identify a cohort of those patients who could potentially participate in further research studies.

Methods {#s2}
=======

Setting {#s2a}
-------

This study took place from March 2014 till July 2016.

Participants {#s2b}
------------

Recruitment was based on self-identification in response to an advertisement in CFS/ME community support networks across Poland, as well as a general advertisement on local radio and social media.

Initially any individuals willing to participate were directed to a phone line. Within days of setting up the phone line, it became clear that this mechanism to identify and recruit potential participants would be overwhelmed. The team therefore directed all potential participants to a website where more information about the study was available and where individuals were invited to self-complete the Fukuda criteria online. If individuals, on completing the online scoring, felt that they met the Fukuda criteria[@R4] within 7 days they were invited to attend the research facility. To be eligible for this study, participants were required to (1) meet Fukuda criteria, (2) be between 25 and 65 years of age and (3) be a resident of Poland. The identification process is shown in [figure 1](#F1){ref-type="fig"}.

![Study protocol.](bmjopen-2018-023955f01){#F1}

### Patient and public involvement {#s2b1}

Patients were not involved in the design of this study. Results from the current study will be disseminated to participants through newsletters in layman terms. We will also communicate our results through a number of other scientific and non-scientific channels including presentations at relevant congresses or in relevant fora.

Clinical assessment {#s2c}
-------------------

Those who fulfilled the eligibility criteria for Centers for Disease Control and Prevention (Fukuda) were invited to attend the research unit at the chronobiology laboratory (windowless and sound-insulated room, temperature 22°C, humidity 60%). They were seen by members of the research team in an assessment that took place over 40 min. Individuals participated in a standardised baseline assessment which comprised a battery of symptom assessment tools. Those screened as fulfilling criteria for CFS/ME[@R4] were also reviewed clinically by a member of the research team in order to determine whether their symptoms were consistent with these criteria, that there were no psychiatric exclusions or other diagnoses that could be associated with CFS/ME or where fatigue was not the primary complaint. Sixty-nine individuals subsequently went on to have a further baseline objective assessment.

Symptom assessment tools {#s2d}
------------------------

Participants completed the following screening symptom assessment tools: Chalder Fatigue Scale,[@R5] Hospital Anxiety and Depression Scale (HADS),[@R8] Epworth Sleepiness Scale (ESS),[@R9] Composite Autonomic Symptom Score 31 (COMPASS 31) and [@R10] Quality of Life Scale (QOLS).[@R10]

Functional assessment of the cardiac and autonomic nervous system {#s2e}
-----------------------------------------------------------------

Cardiovascular and autonomic nervous system measurements were performed with a dedicated high-tech device---Task Force Monitor (TFM, CNSystems, Medizintechnik, Graz, Austria). The main area of TFM application is beat-to-beat analysis of heart rate (ECG) oscillometric and non-invasive continuous blood pressure measurements (oscBP, contBP) and impendance cardiography.[@R15] A detailed of study protocol and its methodology have been presented in our previous articles.[@R23]

In all cases TFM measurements were performed during 10 min of supine rest (phase I) and subsequently asked to standing (phase II) during which changes in heart rate were assessed and where haemodynamic changes were consistent with recognised consensus criteria for a diagnosis of postural tachycardia syndrome (PoTS) made.[@R25]

We classified each individual's autonomic function profile into sympathetic or parasympathetic dominant according to their sympathetico-vagal balance during 10 min of supine rest. This was based on previous studies and assessed using the LF/HF ratio which was considered to suggest a sympathetic dominant pattern if LF/HF was \>1 and parasympathetic if the ratio was \<1.[@R26]

Statistical analyses {#s2f}
--------------------

Statistical characteristics of measured values were presented as arithmetic means and ±SD. The normality of continuous variables distribution was evaluated with the Shapiro--Wilk test depending on distribution characteristics of analysed variables, the independent samples Student's t-test or the Mann--Whitney U test was used to evaluate significance of differences between measured values obtained in the group of each phenotypes. All calculations were performed with the package Statistica V.13.0 (StatSoft), with the assumed level of statistical significance of α\<0.05.

Results {#s3}
=======

Recruitment of the cohort---the prevalence of fatigue in a Polish population {#s3a}
----------------------------------------------------------------------------

During the media campaign, 1400 individuals identified themselves to the research team as fitting, they believed, the criteria for CFS/ME. One thousand and three hundred eight of those subsequently were found not to meet the Fukuda criteria for CFS/ME.

In the 1308 (93%) individuals who identified themselves as fatigued, recognised chronic conditions were identified. These were conditions associated with the symptom of fatigue and therefore could have been the attributable cause for their fatigue symptoms (and therefore not consistent with the Fukuda diagnostic criteria). These fatigue associated conditions were broadly classified into conditions that were: neurological (n=280, 21.5%), neurodegenerative (n=200, 15%), psychiatric (n=654, 50%) and immunologic (n=174, 13.5%) disorders.

Characteristics of a polish cohort of CFS/ME patients meeting the Fukuda criteria {#s3b}
---------------------------------------------------------------------------------

Of the total group with CFS/ME, 41 were female (59.4%). The majority of individuals had a normal BMI (58%) with 24 (35%) being considered overweight and 3 (4.3%) being obese. Two individuals (2.9%) were considered underweight. The majority of individuals were considered to be of a specialist professional group (engineers).

Symptom burden of a polish cohort of CFS/ME patients meeting the Fukuda criteria {#s3c}
--------------------------------------------------------------------------------

The majority of those with CFS/ME had had symptoms for over 2 years with 37% having symptoms for 2--5 years and 21.7% having symptoms for more than 10 years. The vast majority described unrefreshing sleep with impaired short-term memory and concentration (91.3%), postexertional malaise 89%, multi-joint pain without swelling or redness 72.5%, headaches 62.3%, muscle pain 66.7%, sore throat 39.1% and tender cervical or axillary lymph nodes 30.4%.

[Table 1](#T1){ref-type="table"} shows the prevalence of other symptoms identified in those found to have Fukuda CFS/ME. This illustrates the fact that many clinical specialists may come into contact with individuals who may subsequently be identified as having CFS/ME. When COMPASS 31 scores were considered these are shown in [table 2](#T2){ref-type="table"} with 50% of individuals with CFS/ME having symptoms consistent with orthostatic intolerance. HAD scores were high for both anxiety and depression and 43/69 (62%) were found to have ESS scores ≥10, ie, consistent with excessive daytime sleepiness. Considering scores from HADS A & D, 26/69 (38%) had scores consistent with significant anxiety and 22/69 (32%) depression.

###### 

Other symptoms reported at initial assessment, N =69

  Specific symptom                                     No   \%
  ---------------------------------------------------- ---- ------
  IBS                                                  12   17.7
  Migraine                                             17   24.6
  Seasonal allergy                                     8    11.6
  Slight food intolerance/nausea/alcohol intolerance   40   58.1
  Back pain                                            13   18.8
  Tinnitus                                             9    13.0
  Palpitations with no cardiac history                 9    13.0
  Periodical fever                                     8    11.6
  Sensory disturbances                                 0    0
  Chest symptoms with no medical history               15   21.7
  Mood fluctuations                                    30   43.5
  Chronic stress                                       41   59.4
  Overworked/work stress                               34   49.3
  Shift work                                           0    0
  Care work                                            3    4.3
  Newborn care                                         7    10.1
  Frequent infections                                  9    13.0
  Night hyperhidrosis                                  22   31.9
  Sleep disturbance/hypersomnia                        28   40.6
  Unexplained anxiety                                  3    4.3
  Sensory disturbance                                  10   14.5

###### 

Composite Autonomic Symptom Score 31---Autonomic symptoms, N =69

  Specific symptom             No   \%
  ---------------------------- ---- ------
  Orthostatic intolerance      40   50.0
  Dizziness/headaches          41   59.4
  Sudden paleness              25   36.2
  Arrhythmia                   29   42.0
  Dryness eyes mouth           45   65.2
  Vasomotor                    24   34.8
  Secretomotor                 30   43.5
  Upper gastrotract symptoms   38   55.1
  Unknown gastropain           26   37.7
  Constipation                 21   30.4
  Diarrhoea                    28   40.6
  Urinary                      21   30.4
  Sexual failure               19   27.5
  Sleep                        68   98.5
  Pupilomotor                  28   40.6
  Anxiety                      34   49.3

Quality of life of a polish cohort of CFS/ME patients meeting the Fukuda criteria {#s3d}
---------------------------------------------------------------------------------

Quality of life scores assessed using the QOLS were mean (SD) 64 (11). This confirmed that quality of life is significantly impaired in those with Fukuda criteria CFS/ME and well below the expected for a healthy population. When we considered the relationship between quality of life and the other symptoms frequently seen in those with CFS/ME, there were strong significant negative relationships between quality of life and fatigue (p\<0.0001), anxiety (p=0.0009), depression (p\<0.0001) and autonomic symptoms (p=0.04), [figure 2](#F2){ref-type="fig"}. There were no significant relationships between age or daytime sleepiness.

![The relationship between quality of life measured using the QOLS scale and (A) fatigue severity assessed using the fatigue impact scale (B) anxiety measured using the HADS Anxiety Scale (HADS-1) (C) depression measured using the HADS Depression Scale (HADS-2) and D) autonomic symptom burden measured using the COMPASS 31.](bmjopen-2018-023955f02){#F2}

Autonomic function in a polish cohort of CFS/ME patients meeting the Fukuda criteria {#s3e}
------------------------------------------------------------------------------------

When we classified the cohort according to predominance of sympathetic or parasympathetic function, 44/69 (64%) were found to be sympathetic predominant and 25 parasympathetic. When we considered symptom burden between these two phenotypes, there were no significant differences in symptoms or impact on quality of life between the groups ([table 3](#T3){ref-type="table"}). At rest, the sympathetic predominant group had significantly higher heart rate, ER and LF HRV and reduced LVET, PEP and HF HRV compared with the parasympathetic group. The total PSD was comparable between groups however sympatheticovagal balance was different between the phenotypes with increased LF BPV in both diastolic and systolic blood pressure, reduced baroreflex sensitivity in those with the sympathetic dominant phenotype ([table 4](#T4){ref-type="table"}).

###### 

Baseline quality of life scores, N =69

  Variable                    Total group   Sympathetic dominant (n=44)   Parasympathetic dominant (n=25)   P value                 
  --------------------------- ------------- ----------------------------- --------------------------------- --------- ------ ------ --------
  Chalder Fatigue Scale       25.3          3.7                           25.5                              3.8       25.0   3.8    \>0.05
  Fatigue Severity Scale      48.8          8.7                           48.0                              8.5       50.2   9.1    \>0.05
  Fatigue Impact Scale        92.2          26.2                          92.6                              24.6      91.6   29.2   \>0.05
  HADS_A                      9.6           3.4                           9.3                               3.1       10.1   3.9    \>0.05
  HADS_D                      8.5           3.1                           8.5                               3.0       8.6    3.4    \>0.05
  BDI                         17.6          8.1                           18.3                              8.3       16.4   7.9    \>0.05
  Epworth Sleepiness Scale    10.3          5.6                           10.6                              5.3       9.8    6.2    \>0.05
  Quality of Life Scale       63.5          10.9                          62.1                              11.9      65.9   8.8    \>0.05
  Orthostatic Grading Scale   8.4           3.1                           3.5                               3.4       3.4    2.5    \>0.05

###### 

Cardiovascular/autonomic parameters

                                         Variable            Total group (n=69)   Sympathetic dominant (n=44)   Parasympathetic dominant (n=25)   P value                     
  -------------------------------------- ------------------- -------------------- ----------------------------- --------------------------------- --------- -------- -------- --------
  Haemodynamics                          HR                  67.6                 9.2                           70.1                              8.4       63.2     9.0      0.0017
  Sbp                                    117.3               13.3                 118.5                         11.3                              115.2     16.2     \>0.05   
  Dbp                                    79.3                10.6                 79.6                          9.7                               78.8      12.1     \>0.05   
  mBP                                    95.9                11.1                 96.0                          9.9                               95.7      13.2     \>0.05   
  Cardiac impedance                      SI                  52.3                 12.4                          50.8                              12.5      54.9     12.1     \>0.05
  CI                                     3.5                 0.8                  3.5                           0.8                               3.4       0.8      \>0.05   
  TPRI                                   2304.7              747.3                2285.2                        684.3                             2339.0    861.1    \>0.05   
  EDI                                    85.0                19.9                 82.3                          19.9                              89.7      19.5     \>0.05   
  IC                                     62.8                21.2                 59.7                          20.6                              68.2      21.5     \>0.05   
  ACI                                    85.7                34.4                 80.4                          33.8                              95.0      34.3     \>0.05   
  LVWI                                   4.4                 1.1                  4.5                           1.1                               4.4       1.2      \>0.05   
  LVET                                   318.2               17.3                 313.2                         18.2                              327.0     11.1     0.0005   
  TFC                                    31.3                4.5                  30.8                          4.7                               32.3      4.0      \>0.05   
  PEP                                    110.2               12.1                 107.1                         11.3                              115.7     11.6     0.0040   
  STR                                    34.9                4.3                  34.6                          4.7                               35.5      3.4      \>0.05   
  ER                                     35.5                3.3                  36.3                          2.6                               34.2      3.9      0.0092   
  MSER                                   300.8               68.9                 306.2                         72.5                              291.4     62.4     \>0.05   
  REP                                    77.8                16.8                 79.7                          19.8                              74.5      9.1      \>0.05   
  HI                                     0.3                 0.1                  0.3                           0.1                               0.4       0.1      \>0.05   
  RZ                                     187.1               12.2                 185.3                         11.1                              190.4     13.6     \>0.05   
  TAC                                    2.6                 0.7                  2.5                           0.7                               2.8       0.8      \>0.05   
  Heart rate variability                 LFnu-RRI            54.2                 17.2                          62.2                              14.0      40.1     12.7     0.0000
  HFnu-RRI                               45.8                17.2                 37.8                          14.0                              59.9      12.7     0.0000   
  PSD-RRI                                1684.1              1993.7               1604.9                        2166.9                            1823.4    1678.7   \>0.05   
  LF/HF-RRI                              1.7                 1.6                  2.3                           1.8                               0.8       0.4      0.0000   
  Diastolic blood pressure variability   LFnu-Dbp            52.2                 14.7                          59.7                              10.2      38.9     11.7     0.0000
  HFnu-dBP                               14.0                10.4                 11.0                          7.5                               19.3      12.7     0.0004   
  PSD-dBP                                13.6                16.5                 15.2                          19.3                              10.8      9.5      \>0.05   
  LF/HF-dBP                              6.6                 6.2                  8.7                           6.8                               2.8       1.8      0.0000   
  Systolic blood pressure variability    LFnu-sBP            42.1                 13.5                          47.5                              10.7      32.6     12.9     0.0000
  HFnu-sBP                               16.5                10.8                 15.6                          11.0                              18.2      10.4     \>0.05   
  PSD-sBP                                20.2                30.2                 17.5                          16.3                              25.0      45.5     \>0.05   
  LF/HF-sBP                              3.8                 2.8                  4.5                           3.0                               2.5       1.7      0.0019   
  Baroreflex parameters                  Total event count   17.4                 13.6                          21.5                              14.4      10.2     8.4      0.0006
  Total slope mean                       19.6                13.0                 16.7                          8.9                               24.8      17.2     0.0114   
  Total BEI                              70.5                15.1                 72.4                          14.2                              67.0      16.4     \>0.05   

Those with the parasympathetic predominant phenotype were more likely to have had the disease for between 5 and 10 years ([table 5](#T5){ref-type="table"}).

###### 

PoTS (sympathetic, N =44; parasympathetic, N=25)

                                Sympathetic dominant   Parasympathetic dominant   P value                     
  ----------------------------- ---------------------- -------------------------- -------------------- ------ --------
  PoTS                          22                     45.5                       12                   48     \>0.05
  Fatigue period                                                                                              
  6 month--2 years              8                      22.9                       8                    23.5   \>0.05
   2--5 years                   14                     40.0                       12                   35.3   \>0.05
   5--10 years                  4                      11.4                       8                    23.5   0.0492
   More than 10 years           9                      25.7                       6                    17.6   \>0.05
  Fatigue period IQR            2--5 years                                        6  month--2  years          
  Fatigue period in years IQR   8                                                 2.5                         

PoTS, postural tachycardia syndrome.

Prevalence of postural tachycardia syndrome in a Polish cohort of CFS/ME patients {#s3f}
---------------------------------------------------------------------------------

The presence of PoTS is frequently seen in those with CFS.[@R28] A total of 35 (51%) of the CFS group had haemodynamic responses to standing consistent with a diagnosis of PoTS. There was no difference in the proportion of those with PoTS in the sympathetic or parasympathetic groups ([table 5](#T5){ref-type="table"}).

Discussion {#s4}
==========

This study has confirmed for the first time that chronic fatigue is a common symptom experienced by the Polish population and that CFS/ME is an under-recognised syndrome in this group. The key finding of this study is that prevalence is similar to reported data in the other countries and is associated with a large symptom burden and impaired quality of life.

Of the cohort of 1400 who self-presented with fatigue only 69 subsequently were confirmed as having CFS/ME using the Fukuda criteria. This suggests that in Poland there are significant amounts of fatigue related to other conditions, with only a small percentage of those experiencing fatigue having CFS/ME per se (69/1400; 5%).

From the initial responses, we rigorously identified those who met with Fukuda criteria for CFS/ME. We did this by asking individuals to complete the tool, but also using face to face sessions with trained clinicians. We believe therefore, that our cohort represents a well characterised group who we are confident fulfil one of the recognised diagnostic criteria for CFS/ME. When we compared this Polish cohort with CFS/ME to other national cohorts there were some similarities, but also some differences.

Compared with the UK cohort[@R30] having in excess of 6500 individuals collected from the UK NHS Clinical CFS services, the Polish cohort appeared to be of a similar age to the UK cohort with comparable levels of fatigue and illness duration, have similar levels of sleep and cognitive symptoms but less postexertional malaise, muscle pain and headaches. The Polish cohort appeared to have more males than was seen in the UK cohort.

As in previous national cohorts,[@R3] the presence of fatigue in the Polish population was associated with impaired quality of life. As has been seen previously, impaired quality of life associates with the severity of symptoms such as fatigue and autonomic dysfunction, but in contrast to other studies, not daytime sleepiness. Impaired quality of life is also associated with increased anxiety and more depression. As in other series, we would suggest that this association is a secondary phenomenon that is, arising as a consequence of the condition rather than a cause. The fact that we rigorously excluded depression and psychiatric disorders when determining the criteria would be consistent with this.

Our study has also confirmed a high prevalence of the condition PoTS. This form of dysautonomia[@R21] has been recognised as occurring frequently in those with CFS/ME,[@R28] and represents a potential therapeutic target in those with this illness. It is important that clinicians and researchers are aware of the overlap and are trained to identify and manage this condition.

All of these differences might arise because of the self-report nature of the Polish cohort and that the UK cohort was recruited from the National Health Service clinical services which were specifically set up to identify and manage CFS/ME.[@R3] A comprehensive review of the prevalence of CFS/ME in three regions of England involving 143 000 subjects suggested an older cohort with longer disease duration than that seen in the UK clinical services.

An Australian cohort[@R31] was established using similar identification strategies to our Polish cohort with self-report in response to adverts inviting individuals to participate in a research database. Individuals in this cohort were included if they had received the diagnosis from a primary care physician. Again the proportion of females in the Australian cohort was higher than in the Polish cohort

This study has a number of limitations. The case ascertainment process used self-report as the means of identifying those with CFS/ME. It became clear during the radio and television campaign that there was considerable interest, and as a result our recruitment process needed to be changed to facilitate timely screening of those self-presenting with fatigue. It is clear that a thorough, methodologically robust epidemiological study of fatigue and its consequences in a Polish population are now needed.

Our study has confirmed that fatigue is a common and under-recognised symptom affecting the Polish population. It impacts on quality of life and is associated with a range of other symptoms that have been previously recognised in other cohort studies. Despite this, there are no clinical services for fatigue or CFS/ME in Poland and it is poorly understood and infrequently diagnosed. Our research programme now aims to consider the effect of interventions on fatigue in a Polish CFS/ME population.
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